Aldevron Competitors and Similar CompaniesClear all
Aldevron's competitors and similar companies include Catalent and Sangamo Therapeutics.
 Aldevron Aldevron is a company that specializes in manufacturing solutions and regulatory support for both viral and non-viral vector therapies. |  Catalent Catalent is a company that develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, vaccines, and consumer health products. |  Sangamo Therapeutics Sangamo Therapeutics (formerly known as Sangamo BioSciences) is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies. | |
Founding Date | Founding Date 1998 | Founding Date 2007 | Founding Date 1995 |
Type | Type Subsidiary | Type Subsidiary | Type Public |
Tags | |||
Locations | Locations Fargo, US HQ Madison, US | Locations Bridgewater, US HQ Buenos Aires, AR Bruxelles, BE Charleroi, BE Charleroi, BE Charleroi, BE Indaiatuba, BR see more | Locations Brisbane, US HQ Nice Area, FR Cheltenham, GB London, GB Richmond, US |
Employees | Employees 8052% decrease | Employees 12,6955% increase | Employees 35417% increase |
Financial | |||
Revenue (est.) | Revenue (est.) $300m (Y, 2020) | Revenue (est.) $4.4b (FY, 2024) | Revenue (est.) $39.6m (FY, 2025) |
Net income | Net income N/A | Net income ($1b) (FY, 2024) | Net income ($122.9m) (FY, 2025) |
Funding | |||
Total funding raised | Total funding raised N/A | Total funding raised $ 650m | Total funding raised $ 74.2m |
For sources of this data, please see the company profile
View Company Profiles
Catalent
HQ
Bridgewater, US
Catalent is a company that develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, vaccines, and consumer health products.
View companySangamo Therapeutics
HQ
Brisbane, US
Employees
354↑ 17% increase
Sangamo Therapeutics (formerly known as Sangamo BioSciences) is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies.
View company